Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug

Shares of Magenta Therapeutics are down nearly 7% since the opening bell this morning after the company announced the U.S. Food and Drug Administration placed a clinical hold on its clinical program for acute myeloid leukemia and myelodysplastic syndrome.